Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pimavanserin - ACADIA Pharmaceuticals

Drug Profile

Pimavanserin - ACADIA Pharmaceuticals

Alternative Names: ACP-103; BVF-048; Nuplazid; Pimavanserin tartrate

Latest Information Update: 23 Jul 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ACADIA Pharmaceuticals
  • Class Amides; Antidepressants; Antiparkinsonians; Antipsychotics; Behavioural disorder therapies; Fluorinated hydrocarbons; Piperidines; Sleep disorder therapies; Small molecules
  • Mechanism of Action Serotonin 2A receptor antagonists; Serotonin 2A receptor inverse agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Psychotic disorders
  • Phase III Major depressive disorder; Schizophrenia
  • Phase II Agitation
  • Phase I Psychiatric disorders
  • Discontinued Drug-induced akathisia; Drug-induced dyskinesia; Insomnia

Most Recent Events

  • 22 Jul 2021 Efficacy and safety data from phase III HARMONY trial in Psychotic disorders released by ACADIA Pharmaceuticals
  • 03 Jun 2021 Efficacy data from a phase III open label extension study in Psychotic disorders released by Acadia Pharmaceuticals
  • 17 Apr 2021 Interim efficacy and safety data from a phase III trial in Psycotic disorders presented at the 73rd Annual Meeting of the American Academy of Neurology (AAN-2021)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top